Virtual Library
Start Your Search
- Virtual Library Home
- IASLC Library
- Explore Event
-
WCLC 2013
15th World Conference on Lung Cancer
Access to all presentations that occurred during the 15th World Conference on Lung Cancer in Sydney, Australia.
Presentation Date(s):- October 27 - 30, 2013
- Total Presentations: 2517
-
+
P1.05 - Poster Session 1 - Preclinical Models of Therapeutics/Imaging
- Type: Poster Session
- Track: Biology
- Presentations: 25
- Coordinates: 10/28/2013, 09:30 - 16:30, Exhibit Hall, Ground Level
-
+
P1.05-007 - Large scale establishment of genetically diverse patient-derived primary tumor xenografts from resected early stage non-small cell lung cancer (NSCLC) patients
09:30 - 09:30 | Author(s): L. Kim
- Abstract
Loading...
-
+
P1.06 - Poster Session 1 - Prognostic and Predictive Biomarkers
- Type: Poster Session
- Track: Biology
- Presentations: 59
- Coordinates: 10/28/2013, 09:30 - 16:30, Exhibit Hall, Ground Level
-
+
P1.06-034 - MET expression, copy number and oncogenic mutations in early stage NSCLC
09:30 - 09:30 | Author(s): T. John
- Abstract
Loading...
-
+
P1.12 - Poster Session 1 - NSCLC Early Stage
- Type: Poster Session
- Track: Medical Oncology
- Presentations: 23
- Coordinates: 10/28/2013, 09:30 - 16:30, Exhibit Hall, Ground Level
-
+
P1.12-018 - Overall Survival and Smoking Status in Resectable Non-Small Cell Lung Cancer
09:30 - 09:30 | Author(s): L. Spain
- Abstract
Loading...
-
+
MO07 - NSCLC - Targeted Therapies II
- Type: Mini Oral Abstract Session
- Track: Medical Oncology
- Presentations: 14
- Moderators:T. John
- Coordinates: 10/28/2013, 16:15 - 17:45, Bayside Auditorium B, Level 1
-
+
MO07.01 - Clinical benefit of continuing crizotinib beyond initial disease progression in patients with advanced ALK-positive non-small-cell lung cancer
16:15 - 16:20 | Author(s): S.I. Ou
- Abstract
- Presentation
Loading...IASLC Members: To view this content or have the option to purchase this event, click here to login.
Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login. -
+
MO07.02 - Clinical experience with crizotinib in patients with advanced ALK-rearranged non-small cell lung cancer and brain metastases in PROFILE 1005 and PROFILE 1007
16:20 - 16:25 | Author(s): D.B. Costa
- Abstract
- Presentation
Loading...IASLC Members: To view this content or have the option to purchase this event, click here to login.
Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login. -
+
MO07.03 - Crizotinib therapy for patients with advanced ROS1-rearranged non-small cell lung cancer (NSCLC)
16:25 - 16:30 | Author(s): S.I. Ou
- Abstract
- Presentation
Loading...IASLC Members: To view this content or have the option to purchase this event, click here to login.
Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login. -
+
MO07.04 - Clinical Implication of a Population Pharmacokinetic Analysis of XALKORI (crizotinib) in 1,182 Patients with Non-Small Cell Lung Cancer (NSCLC) and 32 Patients with Other Solid Tumors
16:30 - 16:35 | Author(s): D. Nickens
- Abstract
- Presentation
Loading...IASLC Members: To view this content or have the option to purchase this event, click here to login.
Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login. -
+
MO07.05 - DISCUSSANT
16:35 - 16:45 | Author(s): J. Soria
- Abstract
- Presentation
No abstract available for this presentation
IASLC Members: To view this content or have the option to purchase this event, click here to login.
Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login. -
+
MO07.06 - Updated results of a first-in-human dose-finding study of the ALK/EGFR inhibitor AP26113 in patients with advanced malignancies
16:45 - 16:50 | Author(s): D..R. Camidge
- Abstract
- Presentation
Loading...IASLC Members: To view this content or have the option to purchase this event, click here to login.
Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login. -
+
MO07.07 - Combined pan-ERBB and ALK/ROS1/MET inhibition with dacomitinib and crizotinib in advanced non-small cell lung cancer (NSCLC): update of a phase I trial
16:50 - 16:55 | Author(s): G. Giaccone
- Abstract
- Presentation
Loading...IASLC Members: To view this content or have the option to purchase this event, click here to login.
Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login. -
+
MO07.08 - The frequency and impact of ROS1-rearrangement on clinical outcomes in never-smokers with lung adenocarcinoma
16:55 - 17:00 | Author(s): S.M. Lim
- Abstract
- Presentation
Loading...IASLC Members: To view this content or have the option to purchase this event, click here to login.
Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login. -
+
MO07.09 - Feasibility and clinical impact of re-biopsy in advanced non-small cell lung cancer: a prospective multicentric study in real world setting (GFPC study 12-01)
17:00 - 17:05 | Author(s): C. Dujon
- Abstract
- Presentation
Loading...IASLC Members: To view this content or have the option to purchase this event, click here to login.
Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login. -
+
MO07.10 - DISCUSSANT
17:05 - 17:15 | Author(s): N. Pavlakis
- Abstract
- Presentation
No abstract available for this presentation
IASLC Members: To view this content or have the option to purchase this event, click here to login.
Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login. -
+
MO07.11 - A randomised placebo-controlled multicentre phase II trial of erlotinib plus whole brain radiotherapy for patients with advanced non-small cell lung cancer with multiple brain metastases (TACTIC)
17:15 - 17:20 | Author(s): S.M. Lee
- Abstract
- Presentation
Loading...IASLC Members: To view this content or have the option to purchase this event, click here to login.
Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login. -
+
MO07.12 - Phase II study of icotinib and whole brain radiotherapy (WBRT) in patients with brain metastases from non-small-cell lung cancer (NSCLC).
17:20 - 17:25 | Author(s): F. Yun
- Abstract
- Presentation
Loading...IASLC Members: To view this content or have the option to purchase this event, click here to login.
Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login. -
+
MO07.13 - Efficacy of afatinib vs. chemotherapy in treatment-naïve patients with non-small cell lung cancer (NSCLC) harbouring activating EGFR mutations with or without metastatic brain disease
17:25 - 17:30 | Author(s): M. Schuler
- Abstract
- Presentation
Loading...IASLC Members: To view this content or have the option to purchase this event, click here to login.
Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login. -
+
MO07.14 - DISCUSSANT
17:30 - 17:40 | Author(s): M. Ahn
- Abstract
- Presentation
No abstract available for this presentation
IASLC Members: To view this content or have the option to purchase this event, click here to login.
Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login.
-
+
P2.06 - Poster Session 2 - Prognostic and Predictive Biomarkers
- Type: Poster Session
- Track: Biology
- Presentations: 50
- Coordinates: 10/29/2013, 09:30 - 16:30, Exhibit Hall, Ground Level
-
+
P2.06-026 - Association of New York-Esophageal Antigen-1 (NY-ESO-1) promoter methylation and survival in stage III non-small cell lung cancer
09:30 - 09:30 | Author(s): M.S. Liew
- Abstract
Loading...
-
+
P2.09 - Poster Session 2 - Combined Modality
- Type: Poster Session
- Track: Combined Modality
- Presentations: 18
- Coordinates: 10/29/2013, 09:30 - 16:30, Exhibit Hall, Ground Level
-
+
P2.09-007 - Comparison of toxicity and outcomes of concurrent radiotherapy with carboplatin/paclitaxel and cisplatin/etoposide in stage III non-small cell lung cancer
09:30 - 09:30 | Author(s): M.S. Liew
- Abstract
Loading...
-
+
MO16 - Prognostic and Predictive Biomarkers IV
- Type: Mini Oral Abstract Session
- Track: Medical Oncology
- Presentations: 10
- Moderators:S. Toyooka
- Coordinates: 10/29/2013, 16:15 - 17:45, Parkside Auditorium, Level 1
-
+
MO16.05 - DISCUSSANT
16:35 - 16:50 | Author(s): T. John
- Abstract
- Presentation
No abstract available for this presentation
IASLC Members: To view this content or have the option to purchase this event, click here to login.
Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login.
-
+
P3.06 - Poster Session 3 - Prognostic and Predictive Biomarkers
- Type: Poster Session
- Track: Biology
- Presentations: 53
- Coordinates: 10/30/2013, 09:30 - 16:30, Exhibit Hall, Ground Level
-
+
P3.06-006 - Integrated genomic analysis of EGFR-mutant non-small cell lung cancer immediately following erlotinib initiation in patients
09:30 - 09:30 | Author(s): P. Gianikopoulos
- Abstract
Loading... -
+
P3.06-039 - Expression of Mucin 1 in non-small cell lung cancer: Relationship between immunohistochemistry, tumour characteristics and survival
09:30 - 09:30 | Author(s): P.L. Mitchell
- Abstract
Loading...
-
+
P3.10 - Poster Session 3 - Chemotherapy
- Type: Poster Session
- Track: Medical Oncology
- Presentations: 55
- Coordinates: 10/30/2013, 09:30 - 16:30, Exhibit Hall, Ground Level
-
+
P3.10-034 - Is loss of MGMT a therapeutic target in lung cancer?
09:30 - 09:30 | Author(s): H. Do
- Abstract
Loading...
-
+
MO21 - Prognostic and Predictive Biomarkers V - EGFR
- Type: Mini Oral Abstract Session
- Track: Medical Oncology
- Presentations: 12
- Moderators:D.C. Lam
- Coordinates: 10/30/2013, 10:30 - 12:00, Bayside Auditorium A, Level 1
-
+
MO21.05 - Integrated genomic analysis by whole exome and transcriptome sequencing of tumor samples from EGFR-mutant non-small-cell lung cancer (NSCLC) patients with acquired resistance to erlotinib.
10:50 - 10:55 | Author(s): T. Bivona
- Abstract
- Presentation
Loading...IASLC Members: To view this content or have the option to purchase this event, click here to login.
Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login.
